摘要
高胆固醇症是心血管疾病的独立风险因素,严重威胁人们健康。经典的降胆固醇药物他汀类一般疗效显著,但对于家族性高胆固醇血症降脂作用有限,且他汀类存在多种药物不良反应,严重者可导致停药。为此,针对新靶点的新型高胆固醇血症治疗药物研发成为近年来的研究热点。本综述对近年来新型高胆固醇血症治疗药物的研究进展进行总结,以期为未来新型降胆固醇药物的精准用药提供参考。
Hypercholesterolemia was an independent risk factor for cardiovascular disease,which seriously threatened people’s health.Statins were classic cholesterol-lowering drugs which were generally effective.However,lipid-lowering effects of statins on familial hypercholesterolemia were limited.There were many adverse reactions of statins sometimes even led to drug withdrawal.For this reason,the development of new hypercholesterolemia treatment focusing on new targets had become the core of recent research.This review summarized the advances of new treatment to hypercholesterolemia in recent years and provided a reference for the precision medication of new lipid-lowering drugs in the future.
作者
母光妍
刘志艳
张涵煦
周双
王梓凝
赵侠
向倩
崔一民
MU Guang-yan;LIU Zhi-yan;ZHANG Han-xu;ZHOU Shuang;WANG Zi-ning;ZHAO Xia;XIANG Qian;CUI Yi-min(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Institute of Clinical Pharmacology,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第15期2092-2095,共4页
The Chinese Journal of Clinical Pharmacology
基金
国家科技重大专项基金资助项目(2018ZX09201014,2017ZX09304028,2017ZX09101001)
国家自然科学基金资助项目(82073935,81973395,81872940)
北京市科技计划基金资助项目(Z191100007619038)。
关键词
高胆固醇血症
心血管风险
降血脂
新靶点
hypercholesterolemia
cardiovascular risk
lipid-lowering
new targets